Although pembrolizumab and nivolumab (PD-1 inhibitors) have been the more commonly studied immune checkpoint inhibitors in chordoma, durvalumab and FAZ053 (monoclonal antibodies with PD-L1 targets) were applied to limited chordoma treatment regimens with some clinical benefit (47, 48). Here, CD274 is linked to chordoma.